Articles On Patrys (ASX:PAB)

A quick wrap of the ASX’s key winners and losers on Tuesday, September 15. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day. WINNERS TICKER N...

A quick wrap of the ASX’s key winners and losers on Wednesday, September 9. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow have made market moving announcements during the day. Today 393 stocks rose, 998 dec...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Patrys (ASX:PAB) has announced a fully underwritten and non-renounceable rights issue to raise $4.29 million before costs.

On Stockhead today, how a ‘tired’ gold mine transformed shell company Bellevue into a $650m market darling, cobalt has stumbled this year but EV growth is expected to drive demand and prices and is this a new dawn for nickel? But first…   T...

Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the inventor of the Deoxymab technology platform, Dr James Hansen of the Yale School of Medicine, has been awarded a research grant from the US...

Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the appointment of US-based biotechnology executive, Dr Peter Ordentlich, to its Scientific Advisory Board.

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr James Campbell, CEO of Patrys (ASX:...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian company Patrys (ASX:PAB), a therapeutic antibody development company, has announced new pre-clinical data for its lead candidate, PAT-DX1.

According to CEO and managing director Dr James Campbell, “Following ongoing discussions at several partnering events, Patrys has expanded efforts to leverage the platform technology applications of the Deoxymab technology."

It’s shaping up as another coronavirus-related bloodbath on local markets this morning. But within the listed small caps there are still some select winners — particularly health care stocks that report positive clinical updates. Patrys (AS...

A pre-clinical animal study by Australian therapeutic antibody company Patrys (ASX: PAB) has shown the development drug PAT-DX1-NP is able to cross the blood brain barrier and successfully target triple-negative breast cancer brain metastas...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Patrys (ASX:PAB), an Australian therapeutic antibody development company, has announced the upcoming presentation of scientific data regarding its lead candidate, PAT-DX1.

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

In 2019 the culmination of decades worth of work turned several biotechs and life sciences companies into overnight successes. As investors look to defensive growth stocks to compensate for a sluggish economy and with expectations of more h...

The Small-cap stocks have the potential to deliver higher returns within a shorter span of time. As these stocks are underfollowed in the market, so any significant news or that of completion of a project may uplift the share prices. Most o...

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...

Therapeutic antibody developer Patrys (ASX: PAB) has revealed new pre-clinical animal data that points to the potential for its lead candidate drug PAT-DX1 to improve survival rates for patients with highly aggressive forms of brain tumours...

Biotech company Patrys Limited (ASX:PAB) shares got a bump this morning, after some more positive animal tests for its PAT-DX1 cancer treatment. A completed study at Yale School of Medicine shows PAT-DX1 has the potential to improve radiati...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

The cancer drug developer adheres to that perverse law of diminishing returns that states: “The more a biotech company progresses down its chosen therapeutic path, the less it should be valued.” In Patrys’ (ASX:PAB) case, the stock has lost...